Research programme: poliomyelitis vaccine - LG Life Sciences

Drug Profile

Research programme: poliomyelitis vaccine - LG Life Sciences

Alternative Names: LBVC

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class Viral vaccines; Viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Poliomyelitis

Most Recent Events

  • 11 May 2017 LG Life Sciences plans a phase II/III trial for poliomyelitis (Infants, Prevention) in South Korea (IM) (NCT03169725)
  • 28 Aug 2015 Early research in Poliomyelitis (Prevention) in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top